KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizationCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in IntangiblesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and Equipment
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astrazeneca (AZN) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Astrazeneca (AZN) over the last 15 years, with Q4 2025 value amounting to $4.3 billion.

  • Astrazeneca's Free Cash Flow fell 752.43% to $4.3 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $21.5 billion, marking a year-over-year increase of 2071.94%. This contributed to the annual value of $21.5 billion for FY2025, which is 2071.94% up from last year.
  • As of Q4 2025, Astrazeneca's Free Cash Flow stood at $4.3 billion, which was down 752.43% from $6.9 billion recorded in Q3 2025.
  • In the past 5 years, Astrazeneca's Free Cash Flow registered a high of $6.9 billion during Q3 2025, and its lowest value of $303.0 million during Q4 2021.
  • Moreover, its 5-year median value for Free Cash Flow was $3.9 billion (2022), whereas its average is $3.7 billion.
  • As far as peak fluctuations go, Astrazeneca's Free Cash Flow skyrocketed by 17219.96% in 2021, and later plummeted by 752.43% in 2025.
  • Quarter analysis of 5 years shows Astrazeneca's Free Cash Flow stood at $303.0 million in 2021, then soared by 715.51% to $2.5 billion in 2022, then increased by 23.43% to $3.1 billion in 2023, then skyrocketed by 51.64% to $4.6 billion in 2024, then decreased by 7.52% to $4.3 billion in 2025.
  • Its last three reported values are $4.3 billion in Q4 2025, $6.9 billion for Q3 2025, and $5.4 billion during Q2 2025.